Dose finding in aspergillosis

References

• Fourneret-Vivier A, Lebeau B, Mallaret MR, et al. Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000–2002). J Hosp Infect 2006; 62: 22–28
   PubMed Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(Suppl 1)S49–S58
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001; 32: 358–366
   PubMed Web of Science ®Google Scholar
• Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004; 17: 533–540
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, , et al In vivo pharmacodynamics of caspofungin in a murine model of invasive aspergillosis. In: American Society for Microbiology (ASM) (ed) Program and abstract of 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14–17, 2003: abstract M476.
   Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308–329
   PubMedGoogle Scholar
• Chavanet P, Clement C, Duong M, et al. Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate – Fat emulsion in HIV-infected patients with oral candidosis. Clin Microbiol Infect 1997; 3: 455–461
   PubMedGoogle Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001; 32: 358–366
   PubMed Web of Science ®Google Scholar
• Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1412
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487–3496
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, , et al. Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad trial). In: American Society of Hematology (ed.) Program and abstract of 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, 10–13 December, 2005: abstract 3222.
   Google Scholar
• Gubbins PO, McConnell SA, Amseden JR, , et al Comparison of liposomal amphotericin B plasma and tissue concentrations following a single large (15 mg/kg) dose or daily 1 mg/kg dosing. In: American Society for Microbiology (ed.) Program and abstract of 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 30 October–2 November, 2004: abstract A33.
   Google Scholar
• Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696–709
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443–451
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogenic stem cell transplants. Blood 2004; 103: 1527–1533
   PubMed Web of Science ®Google Scholar
• Yamanoi T, Shibano K, Soeda T, et al. Intracranial invasive aspergillosis originating in the sphenoid sinus: a successful treatment with high-dose itraconazole in three cases. Tohoku J Exp Med 2004; 203: 133–139
   PubMed Web of Science ®Google Scholar
• Sanchez C, Mauri E, Dalmau D, et al. Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis?. Clin Infect Dis 1995; 21: 1485–1487
   PubMed Web of Science ®Google Scholar
• Palanisamy A, Chao SD, Fouts M, et al. Central nervous system aspergillosis in an immunocompetent patient: cure in a hospice setting with very high-dose itraconazole. Am J Hosp Palliat Care 2005; 22: 139–144
   PubMedGoogle Scholar
• Imai T, Yamamoto T, Tanaka S, et al. Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery. Intern Med 1999; 38: 829–832
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165–3169
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Invasive Fungal Infections Group of the European Organization for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Briefing FDA document on voriconazole. Available online at www.fda.gov (accessed on 07/05/2006).
   Google Scholar
• Potoski BA, Brown JR. The safety of voriconazole. Clin Infect Dis 2002; 35: 1273–1275
   PubMed Web of Science ®Google Scholar
• Lutsar I, Hodges M, Tomaszewski K, et al. Safety of voriconazole and dose individualization. Clin Infect Dis 2003; 36: 1107–1108
   Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570–1572
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, , et al In vivo pharmacodynamics of caspofungin in a murine model of invasive aspergillosis. In: American Society for Microbiology (ed.) Program and abstract of 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 14–17 September, 2003: abstract M476.
   Google Scholar
• Kartsonis N, Teppler H, Ngai A, , et al Efficacy and safety of higher doses of caspofungin. In: Program and abstract of 2^nd Trends in Medical Mycology (TIMM), Berlin, Germany, 23–26 October 2005, 2005: P-027.
   Google Scholar
• Safdar A, Rodriguez G, Rolston KV, , et al Efficacy of high-dose (100 mg daily) caspofungin (HD-CASP) combination antifungal therapy in cancer patients with invasive fungal infections (IFIs): Case-controlled observational analysis during 2002–2004. In: American Society for Microbiology (ed.) Program and abstract of 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 16–19 December, 2005: abstract M-955.
   Google Scholar
• Safdar A, Rodriguez G, Rolston KV, , et al Efficacy of high-dose caspofungin in 22 cancer patients with invasive fungal infections. In: European Society of Clinical Microbiology and Infectious Diseases (ed.) Program and abstract of 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 2–5 April, 2005: abstract O-343.
   Google Scholar